Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, A-Rum | - |
dc.contributor.author | Kasala, Dayananda | - |
dc.contributor.author | Li, Yan | - |
dc.contributor.author | Hong, Jinwoo | - |
dc.contributor.author | Lee, Wonsig | - |
dc.contributor.author | Jung, Soo-Jung | - |
dc.contributor.author | Yun, Chae-Ok | - |
dc.date.accessioned | 2021-07-30T05:35:17Z | - |
dc.date.available | 2021-07-30T05:35:17Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2016-06 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5577 | - |
dc.description.abstract | Adenovirus (Ad)-mediated cancer gene therapy has been proposed as a promising alternative to conventional therapy for cancer. However, success of systemically administered naked Ad has been limited due to the immunogenicity of Ad and the induction of hepatotoxicity caused by Ad's native tropism. In this study, we synthesized an epidermal growth factor receptor (EGFR)-specific therapeutic antibody (ErbB)-conjugated and PEGylated poly(amidoamine) (PAMAM) dendrimer (PPE) for complexation with Ad. Transduction of Ad was inhibited by complexation with PEGylated PAMAM (PP) dendrimer due to steric hindrance. However, PPE-complexed Ad selectively internalized into EGFR-positive cells with greater efficacy than either naked Ad or Ad complexed with PP. Systemically administered PPE-complexed oncolytic Ad elicited significantly reduced immunogenicity, nonspecific liver sequestration, and hepatotoxicity than naked Ad. Furthermore, PPE-complexed oncolytic Ad demonstrated prolonged blood retention time, enhanced intratumoral accumulation of Ad, and potent therapeutic efficacy in EGFR-positive orthotopic lung tumors in comparison with naked Ad. We conclude that ErbB-conjugated and PEGylated PAMAM dendrimer can efficiently mask Ad's capsid and retarget oncolytic Ad to be efficiently internalized into EGFR-positive tumor while attenuating toxicity induced by systemic administration of naked oncolytic Ad. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.title | Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yun, Chae-Ok | - |
dc.identifier.doi | 10.1016/j.jconrel.2016.02.046 | - |
dc.identifier.scopusid | 2-s2.0-84977911788 | - |
dc.identifier.wosid | 000376444600002 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CONTROLLED RELEASE, v.231, pp.2 - 16 | - |
dc.relation.isPartOf | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.title | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.volume | 231 | - |
dc.citation.startPage | 2 | - |
dc.citation.endPage | 16 | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Proceedings Paper | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | EPIDERMAL-GROWTH-FACTOR | - |
dc.subject.keywordPlus | CANCER GENE-THERAPY | - |
dc.subject.keywordPlus | FACTOR RECEPTOR EGFR | - |
dc.subject.keywordPlus | KUPFFER CELLS | - |
dc.subject.keywordPlus | FACTOR-ALPHA | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | ANTIBODY | - |
dc.subject.keywordPlus | DECORIN | - |
dc.subject.keywordPlus | VECTORS | - |
dc.subject.keywordPlus | MUTANT | - |
dc.subject.keywordAuthor | Adenovirus | - |
dc.subject.keywordAuthor | Oncolytic adenovirus | - |
dc.subject.keywordAuthor | Decorin | - |
dc.subject.keywordAuthor | shRNA | - |
dc.subject.keywordAuthor | c-Met | - |
dc.subject.keywordAuthor | PEGylation | - |
dc.subject.keywordAuthor | PAMAM | - |
dc.subject.keywordAuthor | Dendrimer | - |
dc.subject.keywordAuthor | EGFR | - |
dc.subject.keywordAuthor | Erbitux | - |
dc.subject.keywordAuthor | Cetuximab | - |
dc.subject.keywordAuthor | Cancer | - |
dc.subject.keywordAuthor | Gene therapy | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0168365916301109?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.